Using our proprietary AI platform and metabolomic data from tissues and biofluids of patients, we discover treatments for metabolic diseases with unmet medical needs. With the growth of our database, we intelligently learn more about metabolic diseases and the manifestation of metabolic syndrome.
ReviveMed is an MIT spinout, artificial intelligence (AI)-driven drug discovery platform by uniquely leveraging data from small molecules or metabolites in the human body. Located in the heart of biotech innovation in Cambridge, ReviveMed uniquely overcomes the difficulties of identifying a large set of metabolites for each patient, based on technology that our team developed at MIT and published in Nature Methods. Our AI platform further combines the data from small molecules with other molecular data and translates these data into novel therapeutic insights for drug discovery. Currently, ReviveMed is collaborating with tier-one pharmaceutical companies and pursuing internal drug discovery, initially focused on metabolic diseases, including non-alcoholic fatty liver.
B2B
1 to 25
Seed
$1,500,000
Scaling Up
2018
Pharmaceuticals
Information Services
Healthcare
Biotechnology
N/A
Healthcare
Analytics
Service
Yes
Active
Machine Learning
Machine Perception
Software
N/A
Deep Learning Data Scientist
Cambridge, Massachusetts
Computational Biologist
Cambridge, Massachusetts
AI/ML Professionals
Want to work at ReviveMed?
We can introduce you to the right person at ReviveMed
Potential Customers
Interested in what they do or partnership?
Learn more about how they work